Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
J Biol Chem. 2010 Sep 17;285(38):29491-501. doi: 10.1074/jbc.M110.136770. Epub 2010 Jul 1.
Breast cancers that overexpress the receptor tyrosine kinase ErbB2/HER2/Neu result in poor patient outcome because of extensive metastatic progression. Herein, we delineate a molecular mechanism that may govern this malignant phenotype. ErbB2 induction of migration requires activation of the small GTPases Rac1 and Cdc42. The ability of ErbB2 to activate these small GTPases necessitated expression of p120 catenin, which is itself up-regulated by signaling through ErbB2 and the tyrosine kinase Src. Silencing p120 in ErbB2-dependent breast cancer cell lines dramatically inhibited migration and invasion as well as activation of Rac1 and Cdc42. In contrast, overexpression of constitutively active mutants of these GTPases reversed the effects of p120 silencing. Lastly, ectopic expression of p120 promoted migration and invasion and potentiated metastatic progression of a weakly metastatic, ErbB2-dependent breast cancer cell line. These results suggest that p120 acts as an obligate intermediate between ErbB2 and Rac1/Cdc42 to modulate the metastatic potential of breast cancer cells.
过度表达受体酪氨酸激酶 ErbB2/HER2/Neu 的乳腺癌患者预后不良,因为广泛的转移进展。在此,我们描述了一个可能控制这种恶性表型的分子机制。ErbB2 诱导的迁移需要小 GTPase Rac1 和 Cdc42 的激活。ErbB2 激活这些小 GTPase 的能力需要 p120 连环蛋白的表达,p120 连环蛋白本身通过 ErbB2 和酪氨酸激酶 Src 的信号转导而上调。在依赖 ErbB2 的乳腺癌细胞系中沉默 p120,显著抑制了迁移和侵袭,以及 Rac1 和 Cdc42 的激活。相比之下,过表达这些 GTPase 的组成性激活突变逆转了 p120 沉默的作用。最后,p120 的异位表达促进了迁移和侵袭,并增强了弱转移性、依赖 ErbB2 的乳腺癌细胞系的转移进展。这些结果表明,p120 作为 ErbB2 和 Rac1/Cdc42 之间的必需中间物,调节乳腺癌细胞的转移潜能。